List and liver transplant survival according to waiting time in patients with hepatocellular carcinoma

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 668-677

  Salvalaggio, Paolo R ^a   Felga, G ^a   Axelrod, D A ^b   Della Guardia, B ^a   Almeida, M D ^a   Rezende, M B ^a  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

cancer; classification; Clinical research; hepatology; liver disease: malignant; liver transplantation; malignancy; neoplasia; organ allocation; practice; systems: Milan criteria; waitlist management

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HOSPITAL ADMISSION; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL; TUMOR VOLUME; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; SURVIVAL RATE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; WAITING LISTS;

EID: 84923299904     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13011     Document Type: Article

References (35)

1. El-Serag HB,. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Parkin DM, Bray FI, Devesa SS,. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 (Suppl 8): S4-66.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
4. Wiesner R, Lake JR, Freeman RB, Gish RG,. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006; 12 (12 Suppl 3): S85-S87.
5. Dutkowski P, Oberkofler CE, Bechir M, et al. The model for end-stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: A prospective outcome analysis. Liver Transpl 2011; 17: 674-684.
6. Salvalaggio P, Afonso RC, Pereira LA, Ferraz-Neto BH,. The MELD system and liver transplant waiting-list mortality in developing countries: Lessons learned from Sao Paulo, Brazil. Einstein (Sao Paulo) 2012; 10: 278-285.
7. Washburn K, Halff G,. Hepatocellular carcinoma and liver transplantation. Curr Opin Organ Transplant. 2011; 16: 297-300.
8. Yao FY, Bass NM, Nikolai B, et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policy. Liver Transpl 2003; 9: 684-692.
9. Washburn K, Edwards E, Harper A, Freeman R,. Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system. Am J Transplant 2010; 10: 1643-1648.
10. Sharma P, Harper AM, Hernandez JL, Heffron T, Mulligan DC, Wiesner RH, et al. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation. Am J Transplant 2006; 6: 1957-1962.
11. Freeman RB, Edwards EB, Harper AM,. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6: 1416-1421.
12. Goldberg D, French B, Abt P, Feng S, Cameron AM,. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl 2012; 18: 434-443.
13. Heimbach JK, Hirose R, Olthoff K, et al. eds. Delayed HCC MELD Exception Score Improves Disparity in Access to Liver Transplantation. American Transplant Congress, 2013. Seattle, WA: American Journal of Transplantation.
14. Kulik L, Abecassis M,. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004; 127 (5 Suppl 1): S277-S282.
15. Roberts JP, Venook A, Kerlan R, Yao F,. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl 2010; 16: 925-929.
16. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12: 1260-1267.
17. Chao SD, Roberts JP, Farr M, Yao FY,. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant. 2007; 7: 1594-1600.
18. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
19. Sherman M, Bruix J, Porayko M, Tran T,. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56: 793-796.
20. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
21. Kneteman N, Livraghi T, Madoff D, de Santibanez E, Kew M,. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl 2011; 17 (Suppl 2): S117-S127.
22. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J,. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376-382.
23. Park JW, Amarapurkar D, Chao Y, et al. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int 2013; 33: 327-337.
24. Millonig G, Graziadei IW, Freund MC, et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13: 272-279.
25. Lencioni R, Llovet JM,. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
26. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783-790.
27. Salvalaggio P, Afonso RC, Felga G, Ferraz-Neto BH,. A proposal to grade the severity of early allograft dysfunction after liver transplantation. Einstein (Sao Paulo) 2013; 11: 23-31.
28. Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004; 10: 36-41.
29. Pelletier SJ, Fu S, Thyagarajan V, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl 2009; 15: 859-868.
30. Park SJ, Freise CE, Hirose R, et al. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant 2012; 26: E359-E364.
31. Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D,. Is the treatment of hepatocellular carcinoma on the waiting list necessary ? Liver Transpl 2011; 17 (Suppl 2): S98-S108.
32. Freeman RB Jr., Model for end-stage liver disease (MELD) for liver allocation: A 5-year score card. Hepatology 2008; 47: 1052-1057.
33. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol 2011; 55: 814-819.
34. Lai Q, Avolio AW, Graziadei I, et al. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl 2013; 19: 1108-1118.
35. Schlansky B, Chen C, Austin D, Naugler WE,. eds. Wait List Time Predicts Survival after Liver Transplantation for Hepatocellular Carcinoma: A Cohort Study in the UNOS Registry. American Association of Studies for Liver Disease, 2013. Washington.